Announcements Trials
Browse Landscape

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 36NIH 3INDUSTRY 2NETWORK 1FED 1

Study Type

Interventional 26Observational 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Breast Neoplasms 468Neoplasms 316Carcinoma, Non-Small-Cell Lung 269Prostatic Neoplasms 215Colorectal Neoplasms 208Lung Neoplasms 178Multiple Myeloma 123Melanoma 110Carcinoma, Renal Cell 107Ovarian Neoplasms 94Carcinoma, Hepatocellular 78Pancreatic Neoplasms 69Urinary Bladder Neoplasms 65Stomach Neoplasms 64Neoplasm Metastasis 64Leukemia, Lymphocytic, Chronic, B-Cell 62Colonic Neoplasms 60Leukemia, Myeloid, Acute 53Uterine Cervical Neoplasms 50Recurrence 49Liver Neoplasms 46Lymphoma, Follicular 45Lymphoma 45Leukemia, Myelogenous, Chronic, BCR-ABL Positive 39Esophageal Neoplasms 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 36Lymphoma, Large B-Cell, Diffuse 35Hematologic Neoplasms 35Head and Neck Neoplasms 35Lymphoma, Non-Hodgkin 34

Interventions

mogamulizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Observational × Sezary Syndrome × Clear all
NCT07132567 2025-09-22

Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance

Kyowa Kirin Co., Ltd.

Recruiting
15 enrolled
Lymphoid

Mycosis Fungoides, Sezary Syndrome

NCT05455931 2024-09-04

PROSPER

Kyowa Kirin Co., Ltd.

Active not recruiting
73 enrolled
Lymphoid

Mycosis Fungoides, Sezary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡